The Novartis Malaria Initiative was devised, as a result of a prior-setting contract with the WHO in 2001, to devise a breakthrough treatment for the malaria-"at no profit"-for public health systems. What had commenced as an outstanding action of corporate responsibility had succeeded beyond any expectations.
In the year 2012, for the 2nd year in a row, Novartis had made and disseminated over 100 million ingredients of the anti-malarial drug Coartem (registered company).) Howeverwith the significantly up-scale quantities came increased prices, bringing into question the sustainability of this system. His aim was to expand accessibility to Coartem in the private sector through a low-margin, high-quantity social business structure to consequentially enable the Malaria Initiative to break even and become fiscally sustainable. Was this the correct strategy?
PUBLICATION DATE: March 25, 2014 PRODUCT #: 314103-HCC-ENG
The Novartis Malaria Initiative Case Study Solution
This is just an excerpt. This case is about STRATEGY about STRATEGY & EXECUTION
Related Case Solutions & Analyses:
Regulatory Reform at OSH(C)
KNEX (B): 1991-1994 US Entering a Market Dominated by Giants
Motorola (A)
Vallourecs Venture into Metal Injection Molding
Rise of the New York Port
Barco Projection Systems (C)
Pinkerton (A)
Hospital Sector in 1992
Foulke Consumer Products Inc.: The Southeast Region
2016 Update: Argentina Turns the Page
